Australia's Pharmaceutical Benefits Scheme has been widened to cover treatments for cystic fibrosis, blood cancer and thyroid eye disease, Health Minister Mark Butler announced on Sunday. The changes took effect on Nov. 1, according to Xinhua. Under the expansion, a granule version of Trikafta becomes available to children with cystic fibrosis aged six to 11 who weigh under 30 kilograms.
Why it matters
The PBS sets a ceiling on what patients pay for listed medicines: no more than 25 Australian dollars per prescription, or 7.70 Australian dollars for concession card holders. For families of young children with cystic fibrosis, the gap between that capped price and the open-market cost is substantial. Xinhua reports that without the subsidy, a single prescription of the treatment could exceed 20,300 Australian dollars, roughly 14,200 U.S. dollars.
The granule formulation addresses a practical barrier rather than a new therapeutic one. It is intended for children who struggle to swallow tablets, a group that would otherwise have limited options for a medicine that targets the genetic cause of the condition rather than only its symptoms. The government expects about 3,300 Australians to benefit from the expanded listing each year, Xinhua reports.
Thyroid eye disease and lymphoma additions
Tepezza has been added to the scheme for people with active, moderate-to-severe thyroid eye disease. The government estimates that around 310 Australians will benefit annually. The condition, which affects the tissues around the eyes, has until now had limited subsidised treatment options.
Adcetris, meanwhile, gains broader subsidised access as a first-line option for patients with advanced CD30-positive classical Hodgkin lymphoma, a blood cancer. Xinhua reports that an estimated 370 Australians per year stand to benefit from the change.
The listing for Repatha, used to manage high cholesterol, has also been amended. Eligible patients will be able to collect larger quantities under the government's 60-day prescription initiative, which is designed to reduce the number of pharmacy visits needed for ongoing medicines.
The Canberra Times reported on patient experience with treatment for one of the conditions covered, quoting a patient describing the sensation as "like sand in my eye" — a reminder of the day-to-day burden these conditions place on those affected.
A growing list
The government says it has funded 511 new and amended PBS listings since July 2022. That figure covers the period since the current government took office and is presented by the health department as evidence of sustained investment in subsidised medicine access.
Each listing carries a cost to the federal budget, and the cumulative total is closely watched by health economists and patient groups alike. The department of health has published details of the new listings, and the minister's office framed the changes as part of a broader pattern of expanding coverage.
For patients, the practical effect is immediate: eligibility is determined by the criteria attached to each listing, and clinicians will need to confirm that individual patients meet them. The cystic fibrosis change is limited by both age and weight, meaning some children will fall outside the new criteria.
What to watch
Attention now turns to how quickly the new listings are taken up in practice and whether the government maintains the pace of additions to the scheme in future budget cycles.
